{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035770","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.312437+00:00","generated_at":"2026-06-21T03:12:14.568077+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palisade Bio stops Phase 2 LB1148 trial early; topline data due H1 2023","bullets":["Enrolled 35 of 70 planned patients in Phase 2 PROFILE study for post-surgical adhesions; voluntarily halting further enrollment.","Of those, 31 completed first surgery and 9 completed second surgery (key inflection point for data).","Topline data from the 35 patients expected in first half of 2023.","Company designing a dose optimization study to refine dosing; enrollment anticipated in H1 2023.","CMO Herbert Slade stated collected data is sufficient for evaluation and to guide next steps."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035770","json":"https://secwatch.observer/filing/0001493152-22-035770.json","markdown":"https://secwatch.observer/filing/0001493152-22-035770.md","text":"https://secwatch.observer/filing/0001493152-22-035770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315222035770/0001493152-22-035770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315222035770/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:12:14.568077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}